Bibliography
- MASFERRER JL, ZWEIFEL BS, SEIBERT K, NEEDLEMAN P: Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. (1990) 86:1375–1379.
- MITCHELL JA, AKARASEREENONT P, THIEMERMANN C, FLOWER RJ, VANE JR: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci.USA (1994) 90:11693–11697.
- •Seminal early paper.
- CARTY TJ, MARFAT A: Specific COX-2 inhibitors - realizing the promise of safer NSAIDs. Curt: Opin. Investig. Drugs (1999) 1(2):89–96.
- •Useful review.
- JACKSON CG Therapeutic potential of COX-2 inhibitors in arthritis. Expert Opin. Investig. Drugs (2001) 10 (7):13171–325.
- RYN JV, PAIRET M: Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Expert Opin. Investig. Drugs (1997) 6 (5):609–614.
- TALLEY JJ, BROWN DL, CARTER JS et al.: 4- [5-Methy1-3-phenylisoxazol-4-y1]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. (2000) 43(5):775–777.
- RIENDEAU D, PERCIVAL MD, BRIDEAU C et al.: Etoricwdb (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. ./. Pharmacol. Exp. Ther. (2001) 296(2):558–566.
Websites
- http://www.gsk.com/financial/ product_pipeline.htm